SELLAS Life Sciences Provides Webcast Information for Phase 3 REGAL Study Update on November 14, 2022
November 02 2022 - 8:30AM
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or
the “Company”), a late-stage clinical biopharmaceutical company
focused on the development of novel therapies for a broad range of
cancer indications, today provides webcast information for its
virtual investor event on November 14, 2022, at 8:30 a.m. ET. at
which the Company will provide an update on its Phase 3 REGAL
clinical trial of galinpepimut-S (GPS) in patients with acute
myeloid leukemia.
The event will be facilitated by SELLAS management, including
SELLAS’ President and CEO, Angelos Stergiou, MD, ScD h.c., and
Dragan Cicic, MD, Senior Vice President, Clinical Development, who
will be joined by leading cancer researcher, M. Yair Levy, M.D.,
Director of Hematologic Malignancies Research at the Baylor
University Medical Center, and member of the REGAL Steering
Committee.
Webcast InformationTo attend the live video
webcast, please register or email KCSA Strategic Communications at
SELLAS@kcsa.com.
About SELLAS Life Sciences Group, Inc.SELLAS
Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical
biopharmaceutical company focused on the development of novel
therapeutics for a broad range of cancer indications. SELLAS’ lead
product candidate, GPS, is licensed from Memorial Sloan Kettering
Cancer Center and targets the WT1 protein, which is present in an
array of tumor types. GPS has potential as a monotherapy or in
combination with other therapies to address a broad spectrum of
hematologic malignancies and solid tumor indications. The Company
is also developing GFH009, a small molecule, highly selective CDK9
inhibitor, which is licensed from GenFleet Therapeutics (Shanghai),
Inc., for all therapeutic and diagnostic uses in the world outside
of Greater China.
For more information on SELLAS, please
visit www.sellaslifesciences.com.
Forward-Looking StatementsThis press release
contains forward-looking statements. All statements other than
statements of historical facts are “forward-looking statements,”
including those relating to future events Actual results and the
timing of events could differ materially from those anticipated in
such forward-looking statements as a result of various important
factors. The forward-looking statements herein are made only as of
the date hereof. SELLAS undertakes no obligation to update or
supplement any forward-looking statements to reflect actual
results, new information, future events, changes in its
expectations or other circumstances that exist after the date as of
which the forward-looking statements were made.
Investor ContactAllison SossKCSA Strategic
CommunicationsEmail: SELLAS@kcsa.com Phone: 212.896.1267
Media ContactRaquel Cona / Michaela FawcettKCSA
Strategic CommunicationsEmail: SELLAS@kcsa.com Phone:
516.779.2630
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Sep 2024 to Oct 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Oct 2023 to Oct 2024